

Emily Owen

Senior Product Designer

973.803.6353 | www.eeowen.com

Prescribing Information Patient Information Indication Patient Site This site is intended for U.S. healthcare professionals.

 [Sign in](#)

Now Approved: CIBINQO

CIBINQO is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

NOW APPROVED



Recommended dose



May be considered for patients uncontrolled on 100 mg after 12 weeks

Discontinue therapy if an adequate response is not achieved on 200 mg once daily.

Pills not shown at actual size.

Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.

Introducing CIBINQO

A new oral systemic treatment, with the flexibility to increase the dose if needed

CIBINQO is a JAK inhibitor approved for the treatment of appropriate adult patients with refractory, moderate-to-severe AD who:

- 18+ Are aged 18 years or older
- 1 Are inadequately controlled with other systemic drug products, including biologics, or for whom use of those therapies is inadvisable
- 1x Would prefer an oral, once-daily treatment option

JAK=Janus kinase; AD=atopic dermatitis.

[Full Prescribing Information](#) →

Register Now

Receive updates, resources, and more on CIBINQO and other Pfizer products.

Register →

Sign In →

To report an adverse event, please call [1-800-438-1985](tel:1-800-438-1985)



Extensive work on website for CIBINQO launch. Client: Pfizer, FCB Health

Precision Medicine

Tumor Type Find A Testing Lab Resources

Dedicated to Informing Patient Treatment Through Precision Medicine

Lung Cancer Breast Cancer Ovarian Cancer Prostate Cancer

NEW
Introducing HRRm Testing for Prostate Cancer
 Nearly 90% of patients with advanced prostate cancer have potentially actionable mutations at the tumor level, which can include mutations in genes involved in homologous recombination repair (HRR) and testing for microsatellite instability (MSI) or mismatch repair (MMR).^{1,2}
 Testing for appropriate biomarkers may help guide clinical decisions.^{3,4}
[Learn More >](#)

NEW
Activating HER2 (ERBB2) Mutations Are Actionable in Metastatic NSCLC⁵
 Broad molecular profiling, typically with next-generation sequencing (NGS), is recommended for eligible patients with metastatic non-small cell lung cancer (NSCLC) to identify actionable biomarkers such as activating HER2 (ERBB2) mutations.⁶
[Review Testing Recommendations >](#)

Resources

The latest video and article resources for your patients and your practice.

Dr. Adam ElNaggar
 Director of Genesecologic Cancer Research
 Head Cancer Center and Research Institute
 Memphis, TN

3:45 MIN

The Role of Molecular Testing in Advanced Ovarian Cancer

2:31 MIN

Diagnostic Testing in NSCLC: Preparation for PCR-based EGFR Mutation Testing

1:22 MIN

Role of BRCA Mutations in Breast Cancer

[Explore Resources >](#)


BRCA, breast cancer susceptibility gene; EGFR, epidermal growth factor receptor; ERBB2, erb-b2 receptor tyrosine kinase 2; HER2, human epidermal growth factor receptor 2; HRRm, homologous recombination repair gene mutations; PCR, polymerase chain reaction; PD-L1, programmed death ligand 1.

References
 1. Conception R. Accessed May 10, 2022. <https://www.urologytimes.com/view/role-and-rationale-molecular-testing-advanced-prostate-cancer-2>, Palmboos PL, Hussain MH. *Oncology (Williston Park)*. 2016;30(9):377-385. 5. Cucchiaro V, et al. *Eur Urol*. 2018;73(4):572-582. 4. Kohaar I, et al. *Int J Mol Sci*. 2019;20(8):1813. 5. ENHERTU. Prescribing Information. Daiichi Sankyo, Inc.; 2022. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V6.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed December 7, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Stay Informed

Want to stay up to date on the latest testing guidelines? Sign up to receive relevant Precision Medicine information to help educate your practice.

[Subscribe for Updates >](#)



Extensive work on website for AZ Precision Medicine. Client: Astra, FCB Health

ONO PHARMA USA: Dedicated to the Fight against Disease and Pain

We are an R&D-oriented pharma company from Japan specializing in prescription drug development across oncology, immunology, neurology and specialty research with high unmet medical needs.

Learn more at ONO-USA.com



Research & Development

We deliver our contribution to society by developing drugs that truly benefit patients

We discover and develop innovative new therapies with the latest technology from:

- **Informatics:** Omics analytics and computational chemistry
- **Human disease modeling:** Human iPS cells and genome editing
- **Compound syntheses:** Small-molecule and antibody drugs



Pipeline
Therap
Are

Pipeline
Therapeutic Areas
Innovation
Open Innovation
Mission Statement

Work in Adobe XD on interactive touchscreen panel. Client: ONO Pharma, FCB Health

Important Safety Information | Prescribing Information | Visit Healthcare Professional Site | Treatment Centers | SIGN UP

SPINRAZA
(nusinersen)

STUDY RESULTS | SAFETY | TAKING SPINRAZA | INSURANCE + SUPPORT | RESOURCES + EVENTS | SIGN IN

WHAT COULD SPINRAZA UNLOCK?

See the potential benefits >

Review the safety profile >

A treatment for children and adults with spinal muscular atrophy (SMA)

Ian
age 36
Later-onset (Type 3) SMA treated with SPINRAZA

Sofia
age 2.5
Infantile-onset (Type 1) SMA treated with SPINRAZA

Claire
age 19
Later-onset (Type 2) SMA treated with SPINRAZA

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.

HOW SPINRAZA WORKS
A treatment for pediatric and adult patients with SMA

Attend live events and webcasts >

Find a treatment center >

OVER 2 YEARS OF REAL-WORLD EXPERIENCE

2600+ infants, children, and adults with SMA have been treated with SPINRAZA in the United States.* They range in age from 3 days* to 79 years at first dose**

>35%
of individuals are adults*

>80%
of individuals are in the maintenance dosing phase*

>95%
of individuals who started on SPINRAZA remain on treatment*

*Based on commercial patients in the US (including Puerto Rico) as of December 2018.
**Includes clinical trial patients.
*Clinical studies of SPINRAZA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.

Stay connected
Sign up to learn about the latest news, support information, and upcoming events.

Clinical studies
SPINRAZA was evaluated in individuals with all types of SMA and with varying levels of function

ENDEAR
Infantile-onset SMA
A well-controlled study of motor milestone achievement and survival in individuals aged 30 to 262 days with Type 1 SMA

CHERISH and CS2/CS12
Later-onset SMA
Multiple studies of motor function changes in individuals aged 2 to 16 years with Types 2 and 3 SMA

NURTURE
Presymptomatic SMA
A supportive, open-label study of developmental milestone achievements in infants aged 3 to 42 days diagnosed presymptomatically with SMA

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.

Unlocked: SPINRAZA stories

Important Safety Information | Prescribing Information | SIGN UP

SPINRAZA
(nusinersen)

WHAT COULD SPINRAZA UNLOCK?

Review the safety profile >

See the potential benefits >

A treatment for children and adults with spinal muscular atrophy (SMA)

Ian
age 36
Later-onset (Type 3) SMA treated with SPINRAZA

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.

HOW SPINRAZA WORKS

Important Safety Information | Prescribing Information | Visit Healthcare Professional Site | Treatment Centers | SIGN UP

SPINRAZA
(nusinersen)

STUDY RESULTS | SAFETY | TAKING SPINRAZA | INSURANCE + SUPPORT | RESOURCES + EVENTS | SIGN IN

WHAT COULD SPINRAZA UNLOCK?

See the potential benefits >

Review the safety profile >

A treatment for children and adults with spinal muscular atrophy (SMA)

Ian
age 36
Later-onset (Type 3) SMA treated with SPINRAZA

Sofia
age 2.5
Infantile-onset (Type 1) SMA treated with SPINRAZA

Claire
age 19
Later-onset (Type 2) SMA treated with SPINRAZA

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.

HOW SPINRAZA WORKS
A treatment for pediatric and adult patients with SMA

Attend live events and webcasts >

Find a treatment center >

INDICATION & IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION
Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Conversion of files from Photoshop to Sketch. Created new components and symbols, updated typography, footer, navigation, and ISI tray. Created mobile layouts. Client: CDM-NY, SPINRAZA.

VOI Flip Disc Panel || Playlist 2



Frame 19: Dots flip to change text. People icons come together as a group and their arms animate up




Frame 20: Spinning globe pushes people icons to the right to reveal a white screen




Frame 21: Globe scales down and text appears. Globe continues spinning



Frame 22: Discs flip as the interaction changes



Frame 23: "Let's work..." and the globe disappear and words fill the screen



Frame 23: Words fill the screen around "Let's work..." copy, and interactivity is enabled. Users can swipe away at the disease states. All pixels will repopulate after interactivity and before Playlist 1 restarts

Creation of assets and storyboard for animated flipdisc wall panel, to be displayed at a conference. Client: DDBH, Celgene.



Large panels created for a trade show in Amsterdam.
Client: DDBH, Kymriahh, Novartis.

KYMRIAH[®]
(tisagenlecleucel)

NOW APPROVED IN SWITZERLAND:
The first and only CAR-T cell therapy approved for both DLBCL and ALL¹

KYMRIAH CAR-T

THE TRANSFORMATION OF CANCER TREATMENT BEGINS HERE

Click on an indication below to learn more

DLBCL INDICATION >

KYMRIAH[®] (tisagenlecleucel) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

ALL INDICATION >

KYMRIAH[®] (tisagenlecleucel) is indicated for the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.

Please see the Summary of Product Characteristics and National Succinct Statement.

[NATIONAL SUCCINCT STATEMENT](#)

[BACK](#)
[HOME](#)
[NEXT](#)
[REFERENCES](#)

DLBCL

WHICH PATIENTS ARE RIGHT FOR KYMRIAH?

KYMRIAH is for patients with relapsed or refractory DLBCL who have any of the following clinical characteristics following 2 or more lines of systemic therapy:

- Have relapsed following autologous SCT
- Are being considered for autologous SCT but may have challenges with stem cell collection prior to high-dose chemotherapy
- Are ineligible or not a candidate for autologous SCT due to inability to achieve CR or are unlikely to achieve CR

PATIENTS DO NOT NEED TO BE IN COMPLETE REMISSION

 NO DONOR IS REQUIRED

[NATIONAL SUCCINCT STATEMENT](#)

[BACK](#)
[HOME](#)
[NEXT](#)
[REFERENCES](#)

DLBCL

TRANSFORMING THE TREATMENT OF CD19-EXPRESSING CANCERS¹

KYMRIAH is the only approved CAR-T cell therapy built using the 4-1BB costimulatory domain

- An autologous, adoptive immunocellular therapy, KYMRIAH reprograms a patient's own T-cells to express a CAR targeting cancerous (and other) B-cells

[NATIONAL SUCCINCT STATEMENT](#)

[BACK](#)
[HOME](#)
[NEXT](#)
[REFERENCES](#)

ALL

THE FIRST AND ONLY CAR-T CELL THERAPY APPROVED FOR PAEDIATRIC AND YOUNG ADULT B-CELL ALL¹

Could KYMRIAH be the potentially curative treatment that your patients have been waiting for?

QUALIFIED TREATMENT CENTERS SHOULD CONSIDER KYMRIAH FOR PAEDIATRIC AND YOUNG ADULT PATIENTS UP TO 25 YEARS OF AGE WHO:

- Have not gone into remission following frontline treatment (primary refractory)
- OR
- Have relapsed and cannot achieve remission (chemorefractory)
- OR
- Have had second or subsequent relapse following complete remission
- OR
- Have relapsed following allogeneic SCT

PATIENTS DO NOT NEED TO BE IN COMPLETE REMISSION

 NO DONOR IS REQUIRED

[NATIONAL SUCCINCT STATEMENT](#)

[BACK](#)
[HOME](#)
[NEXT](#)
[REFERENCES](#)


Digital touchscreen panel for a trade show in Amsterdam.
Client: DDBH, Kymriahh, Novartis.



OPTION 1



OPTION 2a



OPTION 2b





The PIQRAY[®] Launch Guide



Your guide to strategy, messaging, branding, and support for the upcoming launch of PIQRAY.

 NOVARTIS

Business Use Only

Not for External Use

Issued: XX 2019

 PIQRAY[®]
(alpelisib) tablets

Welcome to the PIQRAY Launch Guide!

After years of preparation, research, and coordinated efforts with global markets, the global launch of PIQRAY has arrived, marking a major milestone in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC). With its approval, PIQRAY becomes the first and only drug of its kind—furthering Novartis' leadership in oncology. **We are excited to share this moment with you as marketing efforts begin around the globe.**

To help you prepare for local approval, a marketing resource has been created with various information about the PIQRAY brand, including brand strategy, positioning, messaging, and branding.

Please feel free to reach out with any questions. With our coordinated efforts I know we will make this launch as successful as possible.

Sincerely,
The PIQRAY Global Commercial Team

Please remember that any tactics created in your market require local NP4 review and all tactics should take into account other applicable local laws. All content in globally released tactics, inclusive of indication, is based on draft SMPC and must be adapted to reflect approved local label.

 NOVARTIS

Business Use Only

Not for External Use

 PIQRAY[®]
(alpelisib) tablets

Expert Perspectives on Multiple Myeloma

Well-established safety profile²

The adverse reactions listed from CALGB (Study 1) included events reported post-transplant (completion of high-dose melphalan/auto-HSCT) and the maintenance treatment period. In IFM (Study 2), the adverse reactions were from the maintenance treatment period only.

MOST FREQUENTLY REPORTED ADVERSE EVENTS (AEs) IN ≥20% OF POST AUTO-HSCT PATIENTS n (%)

	CALGB (Study 1)		IFM (Study 2)	
	REVLIMID (n=224)	Placebo (n=221)	REVLIMID (n=293)	Placebo (n=280)
Neutropenia ^{a,b}	177 (79.0)	94 (42.5)	178 (60.8)	33 (11.8)
Thrombocytopenia ^{a,b}	162 (72.3)	101 (45.7)	69 (23.5)	29 (10.4)
Leukopenia ^a	51 (22.8)	25 (11.3)	93 (31.7)	21 (7.5)
Anemia	47 (21.0)	27 (12.2)	26 (8.9)	15 (5.4)
Upper respiratory tract infection	60 (26.8)	35 (15.8)	32 (10.9)	18 (6.4)
Bronchitis ^a	10 (4.5)	9 (4.1)	139 (47.4)	104 (37.1)
Nasopharyngitis	5 (2.2)	2 (0.9)	102 (34.8)	84 (30.0)
Gastroenteritis ^a	0 (0.0)	0 (0.0)	66 (22.5)	55 (19.6)
Diarrhea	122 (54.5)	83 (37.6)	114 (38.9)	34 (12.1)
Fatigue	51 (22.8)	30 (13.6)	31 (10.6)	15 (5.4)
Asthenia	0 (0.0)	1 (0.5)	87 (29.7)	53 (18.9)
Pyrexia	17 (7.6)	10 (4.5)	60 (20.5)	26 (9.3)
Rash	71 (31.7)	48 (21.7)	22 (7.5)	17 (6.1)
Muscle spasms	0 (0.0)	1 (0.5)	98 (33.4)	43 (15.4)
Cough	23 (10.3)	12 (5.4)	80 (27.3)	56 (20.0)

- The most frequently reported Grade 3 or 4 reactions adverse reactions (>20% in the REVLIMID arm) included neutropenia, thrombocytopenia, and leukopenia
- In the MM maintenance therapy trials, Grade 3 or 4 neutropenia was reported in up to 59% of REVLIMID-treated patients and Grade 3 or 4 thrombocytopenia in up to 38% of REVLIMID-treated patients
- VTE and ATE are increased in patients treated with REVLIMID
 - Prophylactic medications (aspirin, heparin, or warfarin) could be prescribed for patients at high risk for thrombosis in CALGB¹
 - Protocol did not include systematic thromboprophylaxis in IFM¹
- The serious adverse reactions, lung infection and neutropenia (>4.5%), occurred in the REVLIMID arm
- All serious treatment-emergent AEs (adverse events) were in at least 1% of patients in the lenalidomide maintenance group and at least 1% higher frequency (%) than the placebo maintenance group.
- ADRs (adverse drug reactions) where at least one was considered to be life-threatening (if the outcome of the event was death, it is included with death cases).

>1,000 patients²

Convenient oral dosing



• If tolerated, dose can be increased to 15 mg after 3 cycles

Capsule shown is not actual size.

The China-US Business Alliance invites you to attend a Chinese New Year Celebration!

Guests Welcome

Please join us for cocktails and hor d'oeuvres
Thursday, February 15, 2018; 6-8pm

新年快乐
2018
 Happy Chinese New Year
 Year Of The Dog

Location
 AllianceBernstein L.P.
 1345 Avenue of the Americas,
 41st Floor (Between 54th and
 55th Streets), New York City

RSVP
 Please respond to Christina
 Chen at 212.969.2303 or
 christina.chen@bernstein.com

AB BERNSTEIN

CAPITAL MARKETS OUTLOOK:
JUNE 2018

THE MARKET IS TOO BEARISH ON OIL

The price of oil climbed above \$80 in May, a gain of approximately 25% over the last three months and 75% since last summer. But oil futures contracts suggest investors believe the price should retreat to \$62 by 2024. We think that's too bearish. While we believe today's price is elevated, and is likely to retreat, we believe prices above \$70 are more appropriate, but could be even higher if constraints from Iran and/or Venezuela prove long standing. Here's why.

REGIONAL TENSIONS

First let's review how we got to \$80 oil. The price of oil is always influenced by several factors: the balance between supply and demand, geopolitical conflict in oil producing countries, costs to produce the next marginal barrel of oil, among others. Today is no different.

Global production of oil is about 95 million barrels per day (bbl/day). From time to time, geopolitical discord has been a substantial impediment to reaching production levels. Today that friction is reflected in renewed sanctions on Iran by the US, which are intensifying fears that their production will decline. In fact, after analyzing production levels under previous sanctions, we estimate that Iran's production will likely go down from about 3.8 to 2.8 million bbl/day if the sanctions are the previous ones.

At the same time, the economic collapse in Venezuela, which has already lowered their output, may result in even further supply declines as oil companies potentially pull out of the country. Venezuela produces about one and one-half million bbl/day, down from about 2 million bbl/day before their struggles intensified. We believe these two geopolitical issues are the main reason oil price increases have accelerated during the last few months.

This predicament is amplified by current inventory levels, which have moved from an oversupplied level to a balanced market. Therefore, there is no excess supply buffer, and prices are rising on the anticipation of tight, or even short, supply.

WHAT THE MARKET'S ASSUMING

The Brent crude oil forward curve is much lower than the current, or spot, price. This tells us that the market is expecting oil to fall from where it is today to around \$65 in three years and even more, to \$62 in 2024. The reason for the expected fall in price is because the market has concerns that US shale production will accelerate, and that OPEC will lift its quotas and increase production, both of which will ease tight supply. Investors expect this supply to outstrip demand growth leading to a softer market.

WHY ESTIMATES ARE TOO LOW - OUR VIEW

Our 3-year forecast calls for oil prices to be about \$70, with the price likely higher at the end of that forecast period. Stronger prices make sense: From a demand perspective, solid and synchronized GDP growth world-wide stimulates demand, and from a supply perspective, low capital expenditures globally and cost inflation for the US shale industry all argue for prices at or above \$70, in our opinion. Let's walk through our thesis in detail.


CAPITAL EXPENDITURE DECLINE

There is a natural, geologic decline in oil produced from existing wells. Production from new wells typically compensates for this decline. However, as oil prices started falling in 2014, so did the capital expenditures to explore and drill new wells from drillers outside of the US. This year and next, oil producers are still producing strong growth from projects launched before 2014. However, as the number of new projects has dropped sharply since 2014, and a project typically takes 4-6 years to start production, by 2021, new projects will be delivering much lower growth (Display 1). This reduced supply is supportive of elevated prices for longer.

Display 1
 TITLE HERE

Capital Markets Outlook: June 2018 1

**Investing
 Cross-Border?
 Don't Get Caught
 in the Maze**



Complex Circumstances

- Taxing Situations**
 Complicated and ever-changing local and cross-border income and transfer tax laws
- Fewer Choices**
 Abrupt account closures or drastically increased minimums by major US banks and brokerage firms due to heightened regulatory costs and reporting scrutiny
- Disjointed Offerings**
 Differing advice, fees, offerings and service levels for US and non-US resident family members

Intricate Trade-Offs
 The need for proactive planning advice—and the ability to quantify choices in a tangible way

**Require
 Sophisticated Solutions**

Seamless Advice
 A single, unified advisory team that can serve the family anywhere in the world. That means continuous servicing by the same team—without having to transition because of jurisdiction changes

Flexible Footprint
 Both onshore and offshore platforms and the flexibility to minimize US income, gift, and estate taxes for foreign clients. Ask how they accommodate evolving needs: Can they easily transition family members who become newly subject to US taxation?

Holistic View
 Don't settle for a piecemeal approach. Make sure that providers offer integrated advice and fees for multiple family members, regardless of geography or platform. That includes easy-to-read reporting with a robust snapshot of portfolios and performance across platforms.

Designs for global wealth management firm. Left to right: Invitation for Chinese New Year 2018, Capital Markets Outlook monthly newsletter, mobile layout for cross-border investing. Client: Alliance Bernstein.

PIMCO Log In or Register | Account Access

INVESTMENTS | INSIGHTS | EXPERTS | RESOURCES | OUR FIRM

Awards & Recognition

4 Years.

PIMCO has won Morningstar U.S. Fixed Income Fund Manager in 3 of the last 4 years – a recognition of our ability to deliver attractive long-term risk-adjusted returns for investors across a range of categories and challenging market conditions.

[LEARN MORE >](#)

**JEROME SCHNEIDER
AND TEAM**

**DANIEL IVASCYN AND
ALFRED MURATA**

MARK KIESEL

Award Winning Short-Term Managers

Jerome Schneider and PIMCO's short-term team were named Morningstar's U.S. Fixed Income Manager of the Year 2015. The award notes the team's ability to make "high-conviction purchases and follow(s) a careful approach, focusing on liquidity and minimizing risk."

[LEARN MORE >](#)

Helping you stay ahead of a shifting landscape

Our priority is not just to serve our clients today. It's to serve them even better tomorrow. The scale and pace of change in financial markets has never been greater. And we know it is crucial for investors to adapt. From the early days of our history, PIMCO has had a forward-thinking culture, always looking to help our clients stay ahead of developments that will shape the investment landscape.

1971 **1975** 1986 1997 2000 2003 2004

FUND PAGE
PRODUCT PROFILE

Municipals tend to outperform most other areas of fixed income in rising rate periods.

[WATCH >](#)

When does state-specific customization of a municipal bond portfolio make sense?

[DOWNLOAD >](#)

Contact Your PIMCO Representative

Financial Advisors
Wirehouse: 800.628.1237
Independent: 800.880.8684

RIA and Family Offices
800.842.3815

Institutions
800.877.4626

DISCLOSURES

Investors should consider the investment objectives, risks, charges and expenses of the funds carefully before investing. This and other information are contained in the fund's prospectus and summary prospectus, if available, which may be obtained by contacting your investment professional or PIMCO representative or by visiting www.pimco.com. Please read them carefully before you invest or send money.

A Word About Risk: Investing in the bond market is subject to risks, including market, interest rate, issuer credit, inflation risk, and liquidity risk. The value of most bonds and bond strategies are impacted by changes in interest rates. Bonds and bond strategies with longer durations tend to be more sensitive and volatile than those with shorter durations; bond prices generally fall as interest rates rise, and the current low interest rate environment increases this risk. Current reductions in bond counterparty capacity may contribute to decreased market liquidity and increased price volatility. Bond investments may be worth more or less than the original cost when redeemed. Mortgage and asset-backed securities may be sensitive to changes in interest rates, subject to early repayment risk, and their value may fluctuate in response to the market's perception of issuer creditworthiness; while generally supported by some form of government or private guarantee there is no assurance that private guarantors will meet their obligations.

High-yield, lower-rated, securities involve greater risk than higher-rated securities; portfolios that invest in them may be subject to greater levels of credit and liquidity risk than portfolios that do not. Investors will, at times, incur a tax liability. Income from municipal bonds may be subject to state and local taxes and at times the alternative minimum tax. Equities may decline in value due to both real and perceived general market, economic, and industry conditions. Derivatives may involve certain costs and risks such as liquidity, interest rate, market, credit, management and the risk that a position could not be closed when most advantageous. Investing in derivatives could lose more than the amount invested. Diversification does not ensure against loss.

Alpha is a measure of performance on a risk-adjusted basis calculated by comparing the volatility (price risk) of a portfolio vs. its risk-adjusted performance to a benchmark index; the excess return relative to the benchmark is alpha.

This material contains the current opinions of the manager and such opinions are subject to change without notice. This material has been distributed for informational purposes only and should not be considered as investment advice or a recommendation of any particular security, strategy or investment product. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission. PIMCO is a trademark of Allianz Asset Management of America L.P. in the United States and throughout the world. ©2016, PIMCO

PIMCO Investments LLC, distributor, 1633 Broadway, New York, NY, 10019 is a company of PIMCO.
CMR2016-0404-177822

PIMCO

SUBSCRIBE

US | Individual | [change](#)

PIMCO ON: GET THE APP:

INVESTMENTS

Mutual Funds

ETFs

Closed-End Funds

Managed Accounts

Additional Investment Vehicles

EXPERTS

INSIGHTS

Investment Strategies

Economic and Market Commentary

Viewpoints

PIMCO Blog

RESOURCES

Fund Literature

Webcasts and Conference Calls

Frequently Asked Questions

Tools and Programs

Tax Center

Forms and Applications

Education

Video Library

Subscriptions

OUR FIRM

Who We Are

Firm Leadership

Our Process

Foundation

Contact Us

Media and Press

ESG Framework

Careers

[Privacy Policy](#) | [Terms and Conditions](#) | [Site Map](#)



Copyright PIMCO 2016. All Rights Reserved. Investment Products: NOT FDIC INSURED | MAY LOSE VALUE | NOT BANK GUARANTEED.

PIMCO is a trademark of Allianz Asset Management of America L.P. in the United States and throughout the world. ©2016 PIMCO

Pacific Investment Management Company LLC ("PIMCO") is an investment adviser registered with the U.S. Securities and Exchange Commission ("SEC"). PIMCO Investments LLC ("PIMCO Investments") is a broker-dealer registered with the SEC and member of the Financial Industry Regulatory Authority, Inc. ("FINRA"). PIMCO and PIMCO Investments is solely responsible for its content. PIMCO Investments is the

Design of Awards & Recognition landing page. Client: PIMCO

landing page.



Concepts for a digital timeline about the firm's history of innovation. Explored both a vertical scrolling option and a horizontal layout. Client: PIMCO

The New York Times View in browser

Times Premier

Go Inside the Newsroom and Discover a New Experience — Only for Subscribers

Add Times Premier to your subscription and get exclusive access to **Times Insider** — your backstage pass to the life and drama that transpires daily in our newsroom.

Times Insider — an online feature, takes you beyond the stories, opinion and analysis we provide to actually taking you inside the way we create the journalism that is the benchmark for the industry.

Every day you'll look forward to behind-the-scenes stories such as: Times executive editor Dean Baquet on how the most important articles are chosen for the front page; "By the Book," a series in which reporters discuss the books they're currently reading; and "Reading The Times With..." for a look at how noted public figures react to our news coverage.

Add Times Premier FREE for 8 weeks and enjoy Times Insider.*

[ADD TIMES PREMIER TODAY >](#)

Times Premier
The subscription that takes you inside The Times

This email was sent to you as a subscriber to The New York Times.
This introductory offer is available to New York Times home delivery subscribers and expires on 12/31/2014. This offer is not available to subscribers on a promotional rate, an education rate or billed through a third party. After the introductory period, Times Premier will continue at the regular rate unless you notify us. State and local taxes apply where applicable. Other restrictions apply.
To ensure delivery of emails from The New York Times, please add nytimes@e.newyorktimesinfo.com to your address book.
Privacy Policy | Contact Us | Unsubscribe
© 2014 The New York Times Company | P.O. Box 8041, Davenport, IA 52808-8041

DEAN BAQUET ON ISRAEL COVERAGE, INNOVATION AND THE WEB



“Our hottest debates in the front-page meeting are about obituaries ...”
[Times executive editor Dean Baquet on what deserves to make the front page]

READING THE TIMES WITH GARY SHTEYNGART



Gary Shteyngart shares his view of the Times, in our exclusive feature "Reading The Times With..."

The New York Times logo

The app that delivers more of The Times.

Your digital subscription includes unlimited access to the **NYTimes mobile app** for Android™ — designed to deliver an unrivaled news experience.

[DOWNLOAD NYTIMES APP NOW >](#)

Below are just some of the innovative features we think you'll enjoy...

See Top Stories and Photos With Our Android Widget

Select the Times widget from your widget menu, then drag it to your home screen so you can view vital content in the daily Notification area.

Check Out Our Morning Briefing Every Weekday

Start each weekday better prepared — with the Morning Briefing. It's continually updated from 6 a.m. to 2 p.m. and you'll find it in Top Stories.

Travel

A Solo Traveler's Guide to Meeting People
By Stephanie Rosenbloom | Last Updated: February 20, 2015

The New York Times View in browser

October 2014 | Subscriber Spotlight

Times Premier

This October, our Subscriber Spotlight highlights new Times Insider features like "Reading The Times With" and "By the Book." And don't miss this month's TBooks, "Joints: Easing the Aches and Pains" and "The Election of Francis (The Humble Pope)" now available for download.

Times Insider

It was a busy month. The media columnist David Carr interviewed Executive Editor Dean Baquet before Times Premier subscribers in The Times building. Afterward, a video of the interview was posted on Times Insider. The authors Gay Talese and Delta Ephron and the actress-playwright Anna Deavere Smith read The Times for several days and gave us their thoughts on the coverage. Public Editor Margaret Sullivan and the opinion columnist Frank Bruni told us what books they read and how they read in a feature modeled after By the Book in the Book Review. The event and features were new arrivals in Times Insider. More new features will be coming.

— Times Insider Editors

A Conversation with Dean Baquet
led by David Carr [READ NOW >](#)

NOW AVAILABLE
ACCESS TIMES INSIDER ON YOUR MOBILE DEVICE ON NYTIMES.COM, PLUS ON YOUR NYTIMES IPHONE® AND IPAD® APPS.

Featured TimesTalks

Bradley Cooper talks about "Limitless" and the "Hangover" films, and recounts his path from acting student to leading man.

A Conversation with Bradley Cooper and Dave Izkoff, Times Culture Reporter
[WATCH NOW >](#)

OCTOBER SELECTIONS TBooks

From: AIGA New York <info@aigany.org>
 Subject: Part 4 of 4: Enjoy exclusive savings as a Times subscriber
 Date: January 6, 2011 12:07:44 PM EST
 To: Ben King (ben@brkny.com)

The New York Times View in browser

FUEL FOR ACTIVE MINDS

FOR AS LITTLE AS \$1.88 A WEEK

TRY A DIGITAL SUBSCRIPTION TODAY

For professors or students looking to ground textbook theory in real-world events, a digital subscription to The New York Times is **as low as \$1.88/week**. That's less than the cost of one latte.

We think we can amp you up a little more: Start by paying just \$5 for the first 12 weeks. Then you get 50% off our usual rate after that.

FOR AS LITTLE AS \$1.88 A WEEK **TRY A DIGITAL SUBSCRIPTION TODAY**

This email was sent to you as a registered user of The New York Times.
 Offer available to current college faculty, staff, administrators and students. To qualify for a digital subscription at the college rate, you must also have a valid college or university email address, which usually ends in .edu. Smartphone and tablet apps are not supported on all devices. Does not include e-reader editions, Times Premier content or digital versions of The New York Times Crossword. Prices are subject to change. Other restrictions and taxes may apply.
 To ensure delivery of emails from The New York Times, please add nytimes@e.newyorktimesinfo.com to your address book.
 Privacy Policy | Contact Us | Unsubscribe
 © 2015 The New York Times Company | P.O. Box 8041, Davenport, IA 52808-8041

From: AIGA New York <info@aigany.org>
 Subject: Part 4 of 4: Enjoy exclusive savings as a Times subscriber
 Date: January 6, 2011 12:07:44 PM EST
 To: Ben King (ben@brkny.com)

The New York Times View in browser

UC SANTA BARBARA

The world's finest journalism.
 Get digital access just \$5 for 12 weeks then \$1.88/week at the college rate.

Redeem College Offer >

Uncompromising integrity. Unrivaled coverage. Faculty and students get the finest in journalism with an unlimited digital subscription and discover all that unlimited access to NYTimes.com has to offer. You'll stay fully informed about issues, events and opportunities important to you, and be better prepared in and out of the classroom.

Redeem College Offer >

For just \$5 for 12 weeks, get unlimited access to:

- Immersive Storytelling** by world-class journalists
- Best-in-Class Apps** for iOS® or Android™
- Innovative Multimedia** on topics that inspire you most

This email was sent to you as a registered user of The New York Times.
 Offer available to current college faculty, staff, administrators and students. To qualify for a digital subscription at the college rate, you must also have a valid college or university email address, which usually ends in .edu. Smartphone and tablet apps are not supported on all devices. Does not include e-reader editions, Times Premier content or digital versions of The New York Times Crossword. Prices are subject to change. Other restrictions and taxes may apply.
 To ensure delivery of emails from The New York Times, please add nytimes@e.newyorktimesinfo.com to your address book.
 Privacy Policy | Contact Us | Unsubscribe
 © 2015 The New York Times Company | P.O. Box 8041, Davenport, IA 52808-8041

From: AIGA New York <info@aigany.org>
 Subject:
 Date: January 6, 2011 12:07:44 PM EST
 To: Ben King (ben@brkny.com)

[View in browser](#)

The New York Times

COME BACK TO THE NEW YORK TIMES NOW AND SAVE

Dear Former Times Subscriber,

We invite you, as a valued former subscriber, to take advantage of this special offer to explore all that's new in The Times — and experience once again the incomparable investigative journalism, innovative multimedia and more that the world's finest news source offers.

Come back to The New York Times now and save 50% for 16 weeks (for 26 weeks/for one full year). That's as low as \$1.88 per week, and you'll get unlimited access to NYTimes.com and our apps for smartphone or tablet or both.

RESUBSCRIBE NOW >

Subscribe now and enjoy:

- Unrivaled coverage** of all the news and issues important to you
- Times Video**, bringing you insightful, award-winning takes on the news
- The finest commentary** worldwide, including The Times's exclusive columnists
- New features and blogs** from NYT Cooking to The Upshot, with fascinating, data-driven content on politics, policy and everyday life

Rediscover The Times today and save 50% for 16 weeks (for 26 weeks/for one full year).

RESUBSCRIBE NOW AND SAVE 50% FOR 16 WEEKS!

RESUBSCRIBE NOW >

The New York Times

YOU'VE REACHED YOUR LIMIT OF 10 FREE ARTICLES A MONTH.
To continue reading, subscribe now.

LAST CHANCE! **The September Sale**

60% OFF
FOR 1 FULL YEAR
ON A DIGITAL SUBSCRIPTION

ENDS SEPT. 9 **ACT NOW**

Already a subscriber? [LOG IN](#)

YOU HAVE READ **9 OF 10 FREE ARTICLES** THIS MONTH.

The September Sale **SEE OPTIONS**

The New York Times

The September Sale

60% OFF
FOR 1 FULL YEAR
ON A DIGITAL SUBSCRIPTION

LIMITED TIME OFFER*

Select your digital subscription.

[Compare subscriptions](#)

NYTimes.com
+ Smartphone Apps




60% off for 1 year
Just \$1.50/week†

NYTimes.com
+ Tablet Apps



60% off for 1 year
Just \$2.00/week†

All Digital Access



60% off for 1 year
Just \$3.50/week†

Save with Group Rates

For companies, hotels and organizations
[Click here](#)

Exclusive Education Rates

For students and educators
[Click here](#)

[FREQUENTLY ASKED QUESTIONS](#)

CONTINUE

*Sale orders will be accepted through 09/10/15, 9 a.m. E.T.

†After your first year, regular weekly rates are \$3.75 USD NYTimes.com + Smartphone Apps, \$5.00 USD NYTimes.com + Tablet Apps and \$8.75 USD All Digital Access.

Promotional offer valid for new subscribers that live outside the US. New York Times digital subscriptions are sold separately from e-reader editions, Times Premier content or digital versions of The New York Times Crossword. Mobile apps are not supported on all devices. All subscriptions will automatically renew and your credit card or PayPal account will be charged in advance of each four-week billing period unless canceled. If the subscription is canceled, refunds and termination of access will follow the Terms of Sale policy. Prices are in U.S. dollars unless otherwise specified, and are subject to change. Other restrictions and taxes may apply.

Design and production of banner ads and landing pages for desktop, tablet, and mobile in an ongoing campaign to increase digital subscriptions. Client: The New York Times

The New York Times
**The Digital Sale
Ends Today**
One Year. 60% Off.
Unlimited Access.

SAVE NOW

The New York Times **The Digital Sale Ends Today**
One Year. 60% Off. Unlimited Access.

SAVE NOW

The New York Times **The Digital Sale Now Extended Through October 30**
One Year. 60% Off. Unlimited Access.

SAVE NOW

The New York Times
**The Digital Sale
Ends Today**
One Year.
60% Off.
Unlimited
Access.

SAVE NOW

Design and production of banner ads and landing pages for desktop, tablet, and mobile in an ongoing campaign to increase digital subscriptions. Client: The New York Times

The New York Times

MARCH MADNESS

FULL N.C.A.A. TOURNAMENT COVERAGE ON SALE HERE

INFORMATION INTEGRITY LUXURY

The Premier Destination for Luxury Advertising.
For more information, call Todd Haskell: 212.556.3564, hasketr@nytimes.com

Store
Curated by The New York Times

Free Shipping for orders over \$99.
Enter Code DISCOVERNEW *

Discover the New
Introducing the new face of The New York Times Store. The redesigned site features an enhanced selection and a responsive interface for shopping with ease at home and on the go. Discover the differences now. Shop the new Store at nytimes.com/store.

Personalized

Our best-selling personalized item! This 12" x 19" keepsake reprints every birthday front page in the recipient's life. Comes with an engraved coin and display box. **The Ultimate Birthday Book** \$179.95 | NSAP2176

Vintage Typewriter Key or Vintage Railroad Nail Cufflinks \$150.00 | TYRCLUFF - \$50.00 | NSAP3250

Personalized Oak Wine Barrel \$80.95 | WINEBARREL

Personalized Flask \$25.95 | FLASK

The New York Times Collection

2015 Day Planner \$39.95 | 14243

2015 Three-Month Wall Calendar \$19.95 | 14260

Black Canvas Tote Bags \$38 | 13242 | 13243

Keychain With Charms \$12 | 14158

Order now at nytimes.com/store or call 888.669.2709

* DISCOVERNEW offer applies only to purchases of a minimum of \$99, before shipping and tax, on nytimes.com/store. Offer applies to domestic U.S. ground shipping only. Offer may not be combined with any other offers, discounts or coupons. Offer does not apply to returns or previously purchased orders. Offer ends 11:59 p.m. ET, Saturday, February 28, 2015.

SAVE THE DATE SAVE THE DATE SAVE THE DATE

SAVE THE DATE

MAY 3 2012

SPONSORSHIPS AVAILABLE:

- 15K REACH
- 25K OPPORTUNITY
- 50K IMPACT

THE VISTA @ 1 CHASE MANHATTAN PLAZA
VIP COCKTAILS 5:30PM
DINNER 7PM

R.O.I.*

2012 CORPORATE DINNER

honoring
GUY CHIARELLO • CIO •
JPMorgan Chase
and benefitting

Per Scholas

New York's largest IT workforce development organization

www.perscholas.org
RSVP: events@perscholas.org

***REACH. OPPORTUNITY. IMPACT.**

More than one in five American children are at risk of hunger. Among African-Americans and Latinos, it's 1 in 3.

—Bread for the World


Making a tangible difference in the lives of hungry New Yorkers.


Please join us for
Night of 1000 Friends

Chelsea Piers
Thursday, November 21, 2013
6-9 pm

A fundraiser to benefit
Hispanic Federation's anti-hunger program

For more information please visit us at
www.hispanicfederation.org

 **hispanicfederation** Taking Hispanic Causes to Heart

 **NEW YORK OBSERVER**
Twitter: [HispanicFed](#)

Save the Date

Please join us for
Night of 1000 Friends

A fundraiser to benefit
the Fight Against Hunger/
Lucha Contra el Hambre Campaign

Chelsea Piers
Thursday, November 21, 2013


 **hispanicfederation**
Taking Hispanic Causes to Heart
hispanicfederation.org
Twitter: [HispanicFed](#)

 **NEW YORK OBSERVER**

Save the dates and ad for two NYC-based nonprofits. Clients: Per Scholas, Hispanic Federation



Logo designs for various candidates and small businesses/initiatives. Clients: Red Horse Strategies, Mary's Therapies, Catskill Mountain Foundation.



Dance

Music



fashion

FILM





On left: Wordmarks / typographic explorations for typography class at SVA. On right: Workmark and invitation design for Vertical Players Repertory opera company.

It can destroy an individual or it can fulfill him,
depending on a great deal of luck.




**No one should come here unless
he is willing to be lucky.**

E. B. White, 1955

Here is
Here is
Here is
New York.
New York.
New York.



Typographic explorations of quotes about NYC for typography class at SVA.





Emily is an art director, designer, visual artist, writer, and singer with a professional background that spans a variety of industries.

A native of the suburbs of Chicago, she received her B.A. in Literature from UC Santa Cruz and studied fine art, literature, languages, classics, and graphic and web design at the UC San Diego, Brown University, Parson's School of Design, and School of Visual Arts.

She has extensive experience designing for the nonprofit sector, especially for performing arts groups and organizations working for human rights, peace and justice, environmental conservation, and community improvement. She has also worked in a number of for-profit industries, including media, finance, law, politics, and advertising. She lives in Brooklyn, NY and has freelanced at The New York Times, Alliance Bernstein, Omnicom Health Group, and currently works full-time in pharmaceutical advertising at FCB Health.

Emily Owen

[973.803.6353](tel:973.803.6353) | www.eeowen.com